Herpes Simplex Virus (HSV) Polymerase Chain Reaction (PCR) Testing Global Market Report 2026

The herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market size has grown strongly in recent years. It will grow from $1.18 billion in 2025 to $1.28 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rising global prevalence of hsv infections, increasing awareness of sexually transmitted infections, expansion of molecular diagnostic laboratories, growing adoption of nucleic acid amplification tests, increasing availability of antiviral therapies.
.

The herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growing implementation of routine hsv screening programs, rising demand for rapid point-of-care molecular testing, expansion of precision medicine approaches in infectious diseases, increasing healthcare investments in emerging markets, technological advancements in multiplex and quantitative pcr platforms. Major trends in the forecast period include increasing adoption of real-time pcr for rapid hsv detection, rising demand for early diagnosis in neonatal and genital hsv cases, growing use of multiplex pcr assays for differential diagnosis, expansion of high-sensitivity quantitative pcr testing, increasing integration of automated sample-to-result platforms.

The rising occurrence of infections is anticipated to drive the expansion of the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market in the coming years. Infections occur when harmful microorganisms invade and grow within the body, potentially causing illness. Urbanization contributes to the increase in infections, as higher population densities in cities promote faster transmission of pathogens through close human contact and shared resources. Herpes simplex virus (HSV) polymerase chain reaction (PCR) testing aids by rapidly and accurately detecting HSV DNA, facilitating early diagnosis and treatment, which prevents the infection from worsening or spreading to others. For example, in 2023, the UK Health Security Agency, a government body in the UK, reported that the rate of yeast-related bloodstream infections across England increased by 4% compared to 2022. Hence, the rising occurrence of infections is fueling the growth of the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market.

Leading companies operating in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market are focusing on developing innovative solutions such as point-of-care molecular diagnostics to enable rapid, accurate, and decentralized detection of HSV infections for improved patient management. Point-of-care molecular diagnostics refers to tests that detect pathogens rapidly and accurately at the site of patient care without the need for a central laboratory. For example, in January 2023, Molbio Diagnostics Pvt. Ltd., an India-based medical technology company, launched a Truenat HSV 1/2 chip-based RT-PCR test for diagnosing herpes simplex virus types 1 and 2. This portable, point-of-care assay delivers results in under one hour from genital swabs or cerebrospinal fluid (CSF) using the battery-operated Truelab platform, requires no additional equipment, and holds central drugs standard control organisation (CDSCO) approval in India. It supports rapid detection of active herpes simplex virus (HSV) infections to boost awareness and early treatment amid rising cases.

In May 2024, Bruker Corporation, a US-based scientific instruments and diagnostics company, acquired ELITech Group for an undisclosed sum. With this acquisition, Bruker seeks to broaden its footprint in polymerase chain reaction (PCR) molecular diagnostics and enhance its clinical laboratory diagnostic offerings by utilizing ELITech Group’s molecular diagnostic systems, infectious disease assays, and microbiology solutions, thereby strengthening Bruker’s market presence and service capabilities for clinical laboratories. ELITech Group is a France-based molecular diagnostic company providing herpes simplex virus (HSV) PCR testing solutions.

Major companies operating in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton, Dickinson Company, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Promega Corporation, Meridian Bioscience Inc., Seegene Inc., BioPerfectus Technologies Co. Ltd., altona Diagnostics GmbH, Xi’an Tianlong Science & Technology Co. Ltd., 3B BlackBio Dx Limited, GeneProof s.r.o., Primerdesign Ltd., BioHelix Corporation.

North America was the largest region in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market consists of revenues earned by entities by providing services such as quantitative viral load analysis, confirmation of suspected cases, prenatal and neonatal screening, and monitoring of treatment efficacy. The market value includes the value of related goods sold by the service provider or included within the service offering. The herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market also includes sales of control and calibration materials, viral transport media, swabs and sample collection devices, automated nucleic acid extraction systems, microfluidic cartridges, and laboratory automation accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herpes simplex virus (HSV) polymerase chain reaction (PCR) testing is a molecular diagnostic technique that detects HSV DNA in clinical specimens such as blood, swabs, or cerebrospinal fluid. It provides rapid, highly sensitive, and specific identification of HSV infections, including genital, oral, or neonatal cases. This testing supports early diagnosis, guides antiviral therapy, and helps prevent transmission of the infection.

The key test types of herpes simplex virus (HSV) polymerase chain reaction (PCR) testing include polymerase chain reaction testing, serology testing, and culture testing. PCR testing amplifies and detects specific DNA or RNA sequences to identify pathogens or genetic material with high sensitivity and accuracy. Product types include instruments, reagents and kits, and software, used with sample types such as vesicular swabs or fluid samples, cerebrospinal fluid samples, and blood or serum samples. Applications include clinical diagnostics, research, blood screening, and others, serving hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

Tariffs on imported PCR instruments, reagents, and molecular diagnostic components are influencing the HSV PCR testing market by increasing procurement and operational costs for hospitals and diagnostic laboratories. Segments such as instruments and reagents and kits are most affected, particularly in regions reliant on imported diagnostic systems, including parts of Asia-Pacific, Latin America, and Africa. Higher costs may limit accessibility in low-resource settings; however, tariffs are also encouraging domestic production of PCR kits and localized manufacturing of diagnostic equipment, supporting supply chain resilience and regional innovation over the long term.

The herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market research report is one of a series of new reports that provides herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market statistics, including herpes simplex virus (HSV) polymerase chain reaction (PCR) testing industry global market size, regional shares, competitors with a herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market share, detailed herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market segments, market trends and opportunities, and any further data you may need to thrive in the herpes simplex virus (HSV) polymerase chain reaction (PCR) testing industry. This herpes simplex virus (HSV) polymerase chain reaction (PCR) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.